Galectin Therapeutics Stock Price, News & Analysis (NASDAQ:GALT)

$4.22 +0.03 (+0.72 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$4.22
Today's Range$4.10 - $4.33
52-Week Range$1.28 - $6.74
Volume119,366 shs
Average Volume808,572 shs
Market Capitalization$150.40 million
P/E Ratio-7.54
Dividend YieldN/A
Beta2.67

About Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GALT
CUSIPN/A
Phone+1-678-6203186

Debt

Debt-to-Equity RatioN/A
Current Ratio1.62%
Quick Ratio1.62%

Price-To-Earnings

Trailing P/E Ratio-7.53571428571428
Forward P/E Ratio-8.12
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.10 per share
Price / Book42.20

Profitability

Trailing EPS($0.56)
Net Income$-21,430,000.00
Net MarginsN/A
Return on Equity-1,747.01%
Return on Assets-160.00%

Miscellaneous

Employees7
Outstanding Shares35,640,000

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc (NASDAQ:GALT) issued its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. View Galectin Therapeutics' Earnings History.

When will Galectin Therapeutics make its next earnings announcement?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 27th 2018. View Earnings Estimates for Galectin Therapeutics.

Where is Galectin Therapeutics' stock going? Where will Galectin Therapeutics' stock price be in 2018?

4 Wall Street analysts have issued 12 month price objectives for Galectin Therapeutics' shares. Their predictions range from $2.00 to $10.00. On average, they expect Galectin Therapeutics' share price to reach $6.25 in the next twelve months. View Analyst Ratings for Galectin Therapeutics.

Who are some of Galectin Therapeutics' key competitors?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:

  • Marc Rubin M.D., Chairman of the Board (Age 62)
  • Jack W. Callicutt, Chief Financial Officer (Age 48)
  • Harold H. Shlevin M.D., Ph.D., Chief Operating Officer, Secretary (Age 66)
  • Eliezer Zomer Ph.D., Executive Vice President - Manufacturing and Product Development (Age 68)
  • J. Rex Horton, Executive Director - Regulatory Affairs and Quality Assurance (Age 45)
  • James C. Czirr, Director (Age 62)
  • Gilbert F. Amelio Ph.D., Independent Director (Age 73)
  • Kevin D. Freeman, Independent Director (Age 54)
  • Arthur R. Greenberg, Independent Director (Age 68)
  • John F. Mauldin, Independent Director (Age 65)

Who owns Galectin Therapeutics stock?

Galectin Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.09%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, James C Czirr, Kevin D Freeman, Marc Rubin and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

Who bought Galectin Therapeutics stock? Who is buying Galectin Therapeutics stock?

Galectin Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Galectin Therapeutics stock in the last two years include Kevin D Freeman, Marc Rubin and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics.

How do I buy Galectin Therapeutics stock?

Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of Galectin Therapeutics stock can currently be purchased for approximately $4.22.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $150.40 million. The company earns $-21,430,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Galectin Therapeutics employs 7 workers across the globe.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 Peachtree Industrial Blvd Ste 240, BERKELEY LAKE, GA 30071-1580, United States. The company can be reached via phone at +1-678-6203186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics (GALT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galectin Therapeutics (NASDAQ:GALT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.752.752.752.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.25$6.25$4.63$2.08
Price Target Upside: 42.69% upside42.69% upside84.26% upside6.16% downside

Galectin Therapeutics (NASDAQ:GALT) Consensus Price Target History

Price Target History for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018Roth CapitalBoost Price TargetBuy$3.00 -> $8.00MediumView Rating Details
12/7/2017HC WainwrightReiterated RatingBuy$6.00 -> $10.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/AView Rating Details
4/3/2017FBR & CoReiterated RatingMarket Perform$2.00MediumView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Galectin Therapeutics (NASDAQ:GALT) Earnings History and Estimates Chart

Earnings by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ GALT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018($0.11)N/AView Earnings Details
11/7/2017Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.17)($0.13)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.22)($0.19)ViewN/AView Earnings Details
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
3/18/2015Q4 2014($0.17)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
3/29/2013Q4 2012($0.20)($0.17)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.15)($0.19)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.21)($0.17)ViewN/AView Earnings Details
3/30/2012Q4 2011($0.18)($0.29)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.24)($0.19)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.18)($0.34)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.18)($0.24)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.12)ViewN/AView Earnings Details
11/12/2010Q3 2010($0.12)($0.20)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.28)ViewN/AView Earnings Details
5/12/2010Q1 2010($0.34)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.13)ViewN/AView Earnings Details
11/13/2009Q3 2009($0.24)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.40)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.36)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.17)ViewN/AView Earnings Details
11/7/2008Q3 2008$0.03ViewN/AView Earnings Details
8/8/2008Q2 2008($0.06)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.21)ViewN/AView Earnings Details
3/28/2008Q4 2007($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Galectin Therapeutics (NASDAQ:GALT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.52 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Galectin Therapeutics (NASDAQ GALT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 38.80%
Institutional Ownership Percentage: 10.87%
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Institutional Ownership by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ GALT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2018Kevin D FreemanDirectorBuy2,000$4.10$8,200.0022,043View SEC Filing  
1/26/2018Fund L.P. 10XMajor ShareholderSell244,444$5.43$1,327,330.92View SEC Filing  
1/25/2018James C CzirrDirectorSell205,144$5.45$1,118,034.80View SEC Filing  
12/8/2017Marc RubinDirectorBuy7,000$1.85$12,950.0055,581View SEC Filing  
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.001,083View SEC Filing  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52109,445View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Galectin Therapeutics (NASDAQ GALT) News Headlines

Source:
DateHeadline
NASH Pathogenesis: Better Understanding And A Look At Galectin - Seeking AlphaNASH Pathogenesis: Better Understanding And A Look At Galectin - Seeking Alpha
seekingalpha.com - February 22 at 8:24 AM
Galectin Therapeutics Inc (GALT) Given Average Rating of "Buy" by BrokeragesGalectin Therapeutics Inc (GALT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 2:11 PM
-$0.11 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter-$0.11 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter
www.americanbankingnews.com - February 20 at 5:14 AM
Update On Galectin Therapeutics Potential Entry Into Cancer Market - Seeking AlphaUpdate On Galectin Therapeutics' Potential Entry Into Cancer Market - Seeking Alpha
seekingalpha.com - February 16 at 8:13 AM
Galectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - SlideshowGalectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:31 PM
Galectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment ResearchGalectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 7 at 12:06 AM
Galectin Therapeutics to Present at BIO CEO & Investor ConferenceGalectin Therapeutics to Present at BIO CEO & Investor Conference
feeds.benzinga.com - February 6 at 9:27 AM
Zacks: Brokerages Anticipate Galectin Therapeutics Inc (GALT) Will Post Earnings of -$0.11 Per ShareZacks: Brokerages Anticipate Galectin Therapeutics Inc (GALT) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - February 3 at 5:12 AM
Galectin Therapeutics (GALT) Rating Lowered to Sell at Zacks Investment ResearchGalectin Therapeutics (GALT) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 31 at 12:54 AM
Galectin Therapeutics Inc (GALT) Major Shareholder Fund L.P. 10X Sells 244,444 SharesGalectin Therapeutics Inc (GALT) Major Shareholder Fund L.P. 10X Sells 244,444 Shares
www.americanbankingnews.com - January 30 at 12:14 AM
Galectin Therapeutics Inc (GALT) Director Sells $1,118,034.80 in StockGalectin Therapeutics Inc (GALT) Director Sells $1,118,034.80 in Stock
www.americanbankingnews.com - January 30 at 12:14 AM
Galectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300% - Seeking AlphaGalectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300% - Seeking Alpha
seekingalpha.com - January 29 at 3:29 PM
Is Galectin Therapeutics Inc’s (NASDAQ:GALT) CEO Pay Fair?Is Galectin Therapeutics Inc’s (NASDAQ:GALT) CEO Pay Fair?
finance.yahoo.com - January 29 at 7:16 AM
Galectin Therapeutics Inc (GALT) Receives Average Recommendation of "Hold" from BrokeragesGalectin Therapeutics Inc (GALT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 11:56 AM
Galectin Therapeutics (GALT) Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy - StreetInsider.comGalectin Therapeutics (GALT) Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy - StreetInsider.com
www.streetinsider.com - January 27 at 7:11 AM
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development ProgramsGalectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
finance.yahoo.com - January 25 at 3:28 PM
Galectin Therapeutics Is On To Something Big - Seeking AlphaGalectin Therapeutics Is On To Something Big - Seeking Alpha
seekingalpha.com - January 7 at 5:34 PM
Galectin Therapeutics (GALT) Price Target Increased to $8.00 by Analysts at Roth CapitalGalectin Therapeutics (GALT) Price Target Increased to $8.00 by Analysts at Roth Capital
www.americanbankingnews.com - January 4 at 9:48 AM
Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?
finance.yahoo.com - January 4 at 9:34 AM
Galectin Therapeutics Inc (GALT) Receives Average Rating of "Hold" from AnalystsGalectin Therapeutics Inc (GALT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 2 at 12:44 PM
Galectin Therapeutics (GALT) Downgraded by ValuEngine to "Strong Sell"Galectin Therapeutics (GALT) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - January 2 at 12:50 AM
Galectin Therapeutics Inc (GALT) Short Interest Up 87.7% in DecemberGalectin Therapeutics Inc (GALT) Short Interest Up 87.7% in December
www.americanbankingnews.com - December 31 at 4:22 AM
Head-To-Head Analysis: Galectin Therapeutics (GALT) versus Its RivalsHead-To-Head Analysis: Galectin Therapeutics (GALT) versus Its Rivals
www.americanbankingnews.com - December 21 at 3:28 PM
Reviewing Galectin Therapeutics (GALT) & Its CompetitorsReviewing Galectin Therapeutics (GALT) & Its Competitors
www.americanbankingnews.com - December 21 at 1:16 AM
Galectin Therapeutics Inc (GALT) Springs Up 18% as Illinois Businessman Pours Millions in Credit to Finance NASH Therapy DevelopmentGalectin Therapeutics Inc (GALT) Springs Up 18% as Illinois Businessman Pours Millions in Credit to Finance NASH Therapy Development
finance.yahoo.com - December 20 at 5:13 PM
9 Major Stock Movers to Watch for Wednesday9 Major Stock Movers to Watch for Wednesday
247wallst.com - December 20 at 9:38 AM
Galectin Therapeutics (GALT) Announces $10M Credit Line from Richard E. Uihlein; Sufficient to Cover Expected Expenditures Into 2019Galectin Therapeutics (GALT) Announces $10M Credit Line from Richard E. Uihlein; Sufficient to Cover Expected Expenditures Into 2019
www.streetinsider.com - December 20 at 9:38 AM
Financial Analysis: Galectin Therapeutics (GALT) vs. Its RivalsFinancial Analysis: Galectin Therapeutics (GALT) vs. Its Rivals
www.americanbankingnews.com - December 20 at 9:32 AM
Galectin Therapeutics (GALT) Announces $10M Credit Line from Richard E. Uihlein; Sufficient to Cover Expected ... - StreetInsider.comGalectin Therapeutics (GALT) Announces $10M Credit Line from Richard E. Uihlein; Sufficient to Cover Expected ... - StreetInsider.com
www.streetinsider.com - December 19 at 5:14 PM
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
finance.yahoo.com - December 19 at 5:14 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galectin Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galectin Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - December 18 at 5:13 PM
 Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.11 Earnings Per Share Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - December 14 at 1:30 PM
Galectin Therapeutics (GALT) Provides Corporate Update - StreetInsider.comGalectin Therapeutics (GALT) Provides Corporate Update - StreetInsider.com
www.streetinsider.com - December 14 at 9:43 AM
Galectin Therapeutics Provides Corporate Update at Annual MeetingGalectin Therapeutics Provides Corporate Update at Annual Meeting
finance.yahoo.com - December 14 at 9:43 AM
Regulus Therapeutics (RGLS) and Galectin Therapeutics (GALT) Head-To-Head ReviewRegulus Therapeutics (RGLS) and Galectin Therapeutics (GALT) Head-To-Head Review
www.americanbankingnews.com - December 10 at 11:34 PM
Galectin Therapeutics (GALT) Downgraded by Zacks Investment ResearchGalectin Therapeutics (GALT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 8 at 8:30 PM
Galectin Therapeutics Inc. (GALT) Director Buys $12,950.00 in StockGalectin Therapeutics Inc. (GALT) Director Buys $12,950.00 in Stock
www.americanbankingnews.com - December 8 at 6:48 PM
Galectin Therapeutics Inc. (GALT) to Post FY2018 Earnings of ($0.50) Per Share, Seaport Global Securities ForecastsGalectin Therapeutics Inc. (GALT) to Post FY2018 Earnings of ($0.50) Per Share, Seaport Global Securities Forecasts
www.americanbankingnews.com - December 8 at 12:36 PM
Galectin Therapeutics Inc. (GALT) Receives Average Recommendation of "Buy" from AnalystsGalectin Therapeutics Inc. (GALT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 8 at 11:42 AM
Galectin Therapeutics: Time To Exit - Seeking AlphaGalectin Therapeutics: Time To Exit - Seeking Alpha
seekingalpha.com - December 8 at 9:36 AM
Galectin Therapeutics (GALT) Given New $3.00 Price Target at Roth CapitalGalectin Therapeutics (GALT) Given New $3.00 Price Target at Roth Capital
www.americanbankingnews.com - December 7 at 5:00 PM
Galectin Therapeutics (GALT) Receives "Buy" Rating from HC WainwrightGalectin Therapeutics (GALT) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - December 7 at 8:02 AM
Today’s Research Reports on Stocks to Watch: Allergan plc and Galectin TherapeuticsToday’s Research Reports on Stocks to Watch: Allergan plc and Galectin Therapeutics
finance.yahoo.com - December 6 at 9:46 AM
Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial FailureGalectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure
finance.yahoo.com - December 5 at 5:12 PM
Galectin Therapeutics (GALT) Phase 2b NASH-CX Trial Did Not Reach Primary EndpointGalectin Therapeutics (GALT) Phase 2b NASH-CX Trial Did Not Reach Primary Endpoint
www.streetinsider.com - December 5 at 10:16 AM
Galectin says NASH drug misses main goal of midstage trialGalectin says NASH drug misses main goal of midstage trial
finance.yahoo.com - December 5 at 10:16 AM
Galectin Therapeutics stock drops nearly 50% after negative trial resultsGalectin Therapeutics stock drops nearly 50% after negative trial results
finance.yahoo.com - December 5 at 10:16 AM
Galectin Therapeutics Announces Results from Phase 2b NASH-CX TrialGalectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
finance.yahoo.com - December 5 at 10:16 AM
Galectin slumps after NASH drug misses main goal of mid-stage trialGalectin slumps after NASH drug misses main goal of mid-stage trial
finance.yahoo.com - December 5 at 10:16 AM
Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
finance.yahoo.com - December 4 at 5:14 PM

SEC Filings

Galectin Therapeutics (NASDAQ:GALT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galectin Therapeutics (NASDAQ:GALT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galectin Therapeutics (NASDAQ GALT) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.